The Global Threat January – March 2024

dsm-firmenich e




Figure 1. Global map of mycotoxin prevalence and risk in different regions.

| . | , , | | | 6 | | | | |
|---|----------|----------|--------------|---|--|--|--|--|
| | 26 – 50% | 51 – 75% | 76 – 100% | | | | | |
| of samples above risk threshold No samples tested | | | | | | | | |
| ← | | | | | | | | |
| Moderate risk | | | Extreme risk | | | | | |

dsm-firmenich has used diligent care to ensure that the information provided herein is accurate and up-to-date, however, dsm-firmenich makes no representation or warranty, either expressly or implied, of the accuracy, reliability, or completeness thereof. The information provided herein contains scientific and product information for business to business use and does not constitute or provide scientific or medical advice, diagnosis, or recommendation for treatment. Country or region-specific information should be considered when labeling or advertising to the final consumer. In no event shall dsm-firmenich be liable for any damages arising from or reliance upon, or use of, any information provided herein. The content of this document is subject to change without further notice. Please contact your local dsm-firmenich representative for further details. All trademarks listed in this document are either (registered) trademarks of, or trademarks licensed by, the dsm-firmenich group of companies in the Netherlands and/or other countries, unless explicitly stated otherwise.

Mycofix® is not available in the US and Canada.

ACKNOWLEDGEMENTS

Special thanks go to Biofarma Feedlab Argentina and Anita Mengyan, Tiergesundheitsdienst Bayern e.V. for sharing their mycotoxin analysis results as part of this survey. Mycotoxin Report is published by DSM Austria GmbH, Erber Campus, 3131 Getzersdorf, Austria, Tel: +43 2782 8030, www.dsm.com/anh ©Copyright dsm-firmenich, 2024. All rights reserved. Any kind of reprint, reproduction, or any other kind of usage – whether partially or to the full extent – only allowed upon prior written approval by dsm-firmenich.

Risk Level


The risk level expresses the percentage of samples testing positive for at least one mycotoxin above the threshold level in parts per billion (ppb).


Recommended risk threshold of major mycotoxins in ppb

| Afla | ZEN | DON | T2 | FUM | OTA |
|------|-----|-----|----|-----|-----|
| 2 | 50 | 150 | 50 | 500 | 10 |

| | | | | | Ε. | | - | | | | | |
|--------|----------------|-------------|------------|--|----|----|-----------------|-------------|------------|-----|----------|-----|
| | | | | | | | | | | | | |
| | | | | | | | | | | | | • |
| | | | | | | | | | | N. | - | ~ |
| | | | | | | | | | | | ~ | |
| | | Prevo | | | | | | | | | | |
| | 95% | Afla ZEN | 389 799 | | | | | | | ~ | •• ··· · | . 1 |
| Ĭ | Total Risk 95% | DON | 95% | 6 | | | | 1 | | | | |
| 2 | alR | T2 FUM | 09 959 | 6 | 1 | 1 | | | alance: | | | |
| ť | 5 L | OTA | 109 | % | | | Č | Afla ZEN | 10% 40% | | | |
| | | | | | | | East Asia | DON | 80% | | | |
| _ | | | | 2 | | | st A | T2 FUM | 0% 100% | | | |
| 2 | | | | | | | ыR | ΟΤΑ | 0% | | | |
| ר ר | | | | | | | | | | | | |
| 3 | | | | 1. Contraction 1. Con | | | sia | Prevo | alance: | | | |
| | | 1 | لمر | 13 | | | st A | Afla ZEN | 74% 38% | | | |
| | | | | 1. F | | | - Ed | DON | 50% | 1.1 | | |
| 2 | | | | | | | South-East Asia | T2 FUM | 0% 97% | | | |
| | | | | | | | ů v | ΟΤΑ | 21% | | | |
| | | | | | | 4 | | | | | | |
| | | | | | | | | | 2 | | | |
| | | | | | | | | | 15 | | | |
| 1 | Drov | valana | | | | | | | | | | |
| | Aflo | ı 14 | % | | | | | | | | | |
| | ZEN DOI | | % | | | 12 | | | | | | |
| | T2 | C |)% | | | | | | | | | |
| | FUN OTA | | % !% | | | | | | 4 | | | |
| | | 14 | 10 | | | | | | | | | |
| | | | | | | | | | | | | |

The Global Threat -January to March 2024






Animal colours indicate the risk posed to this species by the prevalence and concentration of each mycotoxin in all samples from this region (light orange=moderate to red=extreme see color code page 2)

% Contaminated samples January–March 20243 🔳 and January–March 2023 🔳

| Total samples: 2 638 | Afla | ZEN | DON | T-2 | FUM | OTA |
|---------------------------|-------|-------|-------|-------|-------|------|
| Number of samples tested | 2 212 | 2 531 | 2 559 | 1 971 | 2 017 | 1953 |
| % Contaminated samples | 22% | 66% | 69% | 26% | 53% | 9% |
| Average of positive (ppb) | 6 | 95 | 632 | 35 | 330 | 8 |
| Median of positive (ppb) | 3 | 23 | 221 | 14 | 104 | 3 |
| Maximum (ppb) | 132 | 4810 | 43891 | 1731 | 12368 | 331 |



Animal colours indicate the risk posed to this species by the prevalence and concentration of each mycotoxin in all samples from this region (light orange=moderate to red=extreme see color code page 2)

% Contaminated samples January–March 20243 🔳 and January–March 2023 🔳


| Total samples: 67 | Afla | ZEN | DON | T-2 | FUM | ΟΤΑ |
|---------------------------|------|-----|-------|-----|------|-----|
| • | | | | | | |
| Number of samples tested | 67 | 67 | 67 | 67 | 67 | 67 |
| % Contaminated samples | 22% | 82% | 58% | 27% | 94% | 1% |
| Average of positive (ppb) | 2 | 40 | 368 | 14 | 395 | 1 |
| Median of positive (ppb) | 1 | 7 | 297 | 11 | 305 | 1 |
| Maximum (ppb) | 6 | 263 | 1 152 | 55 | 1509 | 1 |

| | | C |
|---|---|---|
| | | C |
| | M | C |
| | | C |
| | | C |
| 2 | | C |
| | | |


Animal colours indicate the risk posed to this species by the prevalence and concentration of each mycotoxin in all samples from this region (light orange=moderate to red=extreme see color code page 2) % Contaminated samples January-March 20243 and January-March 2023

| Total samples: 172 | Afla | ZEN | DON | T-2 | FUM | ΟΤΑ |
|---------------------------|------|-----|-------|-----|-----|-----|
| Number of samples tested | 172 | 172 | 172 | 172 | 172 | 172 |
| % Contaminated samples | 13% | 65% | 84% | 3% | 46% | 6% |
| Average of positive (ppb) | 34 | 25 | 487 | 53 | 112 | 8 |
| Median of positive (ppb) | 4 | 9 | 241 | 56 | 58 | 6 |
| Maximum (ppb) | 214 | 433 | 5 091 | 89 | 738 | 24 |





The Global Threat -January to March 2024



| 🍷 🚗 🛒 🖛 🥐 | 2024 2023 Afla | 61 37 | |
|-----------|-------------------|-----------------|---|
| 🤘 🐂 🗗 🛏 🥐 | 2024 2023 ZEN | 41 59 | |
| y 🛪 🗗 🛏 🥐 | 2024 2023 DON | 17 72 | |
| 🤘 🐂 🛒 🖙 🥐 | 2024 2023 T-2 | 57 | |
| 🍷 📻 🛒 🖙 🥐 | 2024 2023 FUM | 59 87 | 7 |
| ¥ 🖷 🖻 🗯 😨 | 2024 2023 OTA | 23 56 | |

Animal colours indicate the risk posed to this species by the prevalence and concentration of each mycotoxin in all samples from this region (light orange=moderate to red=extreme see color code page 2)

% Contaminated samples January–March 20243 🔳 and January–March 2023 🔳

| Total samples: 595 | Afla | ZEN | DON | T-2 | FUM | OTA |
|---------------------------|------|-------|-------|-----|---------|-----|
| Number of samples tested | 595 | 594 | 595 | 586 | 594 | 586 |
| % Contaminated samples | 61% | 41% | 17% | 57% | 59% | 56% |
| Average of positive (ppb) | 27 | 56 | 443 | 31 | 1566 | 17 |
| Median of positive (ppb) | 15 | 34 | 217 | 26 | 635 | 5 |
| Maximum (ppb) | 253 | 1 122 | 9 700 | 113 | 489 698 | 441 |

| | | C | 2024 2023 | Afla | 6 | | | |
|---------------------------------------|---|----------|---------------------|------|----------|----|-----------|-----------------|
| ý | | ? | 2024 2023 | ZEN | | 38 | | 82 |
| Č. | M | ? | 2024 2023 | DON | | | | 74 78 |
| ų, | | | 2024 2023 | T-2 | 2 17 | | | |
| e e e e e e e e e e e e e e e e e e e | | ? | 2024 2023 | FUM | | | 50 | |
| ý | | C | 2024 2023 | OTA | 3 | | | |

Animal colours indicate the risk posed to this species by the prevalence and concentration of each mycotoxin in all samples from this region (light orange=moderate to red=extreme see color code page 2)

% Contaminated samples January-March 20243 and January-March 2023

| Total samples: 403 | Afla | ZEN | DON | T-2 | FUM | ΟΤΑ |
|---------------------------|------|-------|--------|-----|--------|-----|
| Number of samples tested | 400 | 403 | 403 | 403 | 403 | 400 |
| % Contaminated samples | 18% | 82% | 74% | 17% | 57% | 3% |
| Average of positive (ppb) | 7 | 136 | 1836 | 28 | 3 846 | 3 |
| Median of positive (ppb) | 2 | 40 | 726 | 15 | 1534 | 3 |
| Maximum (ppb) | 111 | 2 310 | 20 963 | 276 | 96 316 | 8 |

| V | | | C |
|----------|---|---|----------|
| ý | | | C |
| м. | M | - | 6 |
| | | | C |
| ý | | | C |
| | | | C |

page 2)

| Total samples: 1455 | Afla | ZEN | DON | T-2 | FUM | ΟΤΑ |
|---------------------------|------|------|-------|------|--------|-------|
| Number of samples tested | 1455 | 1455 | 823 | 1455 | 1066 | 1 327 |
| % Contaminated samples | 20% | 49% | 49% | 18% | 60% | 1% |
| Average of positive (ppb) | 2 | 91 | 638 | 38 | 2 089 | 5 |
| Median of positive (ppb) | 2 | 45 | 324 | 36 | 1460 | 3 |
| Maximum (ppb) | 28 | 946 | 9 856 | 113 | 17 820 | 15 |

Animal colours indicate the risk posed to this species by the prevalence and concentration of each mycotoxin in all samples from this region (light orange=moderate to red=extreme see color code

% Contaminated samples January-March 20243 and January-March 2023

The Global Threat -January to March 2024

Spectrum 380° and Spectrum Top°50

Only analyzing for single mycotoxins can lead to underestimation of the detrimental effects of mycotoxins on animal health and performance. Our long-term monitoring of mycotoxins in different commodities shows that co-occurrence of mycotoxins is the rule and not the exception. Here we need support of state-of the art analytical methods based on LC-MS/ MS. These allow to detect multiple mycotoxins in one run. The high sensitivity of the method is important, as already moderate levels of mycotoxins can have a detrimental effect. This is especially true in case of co-contamination.





Spectrum 380®:

The most advanced and comprehensive mycotoxin analysis available

It detects > 800 different mycotoxins (including masked and modified forms and emerging mycotoxins), fungal metabolites as well as plant and bacterial toxins and metabolites.

This is not a routine analysis but it is done in special cases and/or also of course as part of research of future objectives.

Spectrum 380[®] is developed and conducted by the world's leading independent mycotoxin research lab at the Department of Agrobiotechnology (IFA-Tulln) at the University of Natural Resources and Life Sciences Vienna and offered through cooperation with Performance Solutions plus Biomin.

Spectrum Top[®]50:


The most comprehensive mycotoxin analysis commercially available

It detects > 50 different mycotoxins (including masked and modified forms), emerging mycotoxins and fungal metabolites.

The Spectrum Top® 50 method was developed by scientists of Romer Labs, a leading global supplier of diagnostic solutions for food and feed safety.

Multiple mycotoxin occurrence






Total 330 samples from 23 countries; 264 000 points of analysis

Mycotoxins & metabolites

| Metabolite | Prevalence | | Average | Maximun |
|------------------------|------------|-----|---------|---------|
| Tryptophol | | 84% | 630 | 78 200 |
| Aurofusarin | | 80% | 409 | 14 744 |
| Moniliformin | | 80% | 95 | 1233 |
| Asperglaucide | | 73% | 117 | 6 706 |
| Equisetin | | 72% | 60 | 2 808 |
| Flavoglaucin | | 72% | 509 | 95 136 |
| Siccanol | | 72% | 267 | 7 152 |
| Infectopyron | | 70% | 13 788 | 229 248 |
| Enniatin B | | 70% | 71 | 2 651 |
| Culmorin | | 69% | 136 | 2 310 |
| Brevianamid F | | 68% | 57 | 1663 |
| Emodin | | 67% | 48 | 2 197 |
| Abscisic acid | | 66% | 323 | 7 685 |
| Beauvericin | | 65% | 15 | 193 |
| Daidzin | | 65% | 28 017 | 237 100 |
| Asperphenamate | | 65% | 197 | 8 693 |
| Daidzein | | 65% | 3 052 | 20 440 |
| Enniatin B1 | | 62% | 44 | 1037 |
| Tenuazonic acid | | 62% | 381 | 5 448 |
| Bikaverin | | 62% | 33 | 605 |
| Neoechinulin A | | 61% | 465 | 79 008 |
| Fellutanine A | | 60% | 52 | 1288 |
| Genistin | | 58% | 44 393 | 317 400 |
| Alternariolmethylether | | 58% | 17 | 402 |
| 15-Hydroxyculomorin | | 56% | 593 | 14 770 |
| Zearalenone | | 55% | 74 | 4 961 |
| Alternariol | | 54% | 68 | 4 627 |
| Genistein | | 53% | 2 972 | 17 332 |
| Altersetin | | 52% | 57 | 915 |
| Deoxynivalenol | | 52% | 522 | 8 120 |
| Rugulusovin | | 52% | 84 | 3 0 4 4 |
| Chrysogin | | 51% | 49 | 1 013 |

Positive Samples [%] for metabolites present in >50% of samples (orange bars indicate regulated or guideline mycotoxins; red bar indicates a masked mycotoxin). Cut off for all metabolites 1 ppb (except for aflatoxins 0.5 ppb). Average of positives and Maximum are presented in ppb.





The Global Threat -January to March 2024

Overview of the most frequently found mycotoxins, their masked and modified forms as well as emerging mycotoxins in all samples and finished feed

ALL samples (n=1 618)

| Metabolite | Prevalence | | Average | Maximum |
|----------------------------|---------------------------|----------------|---------|---------|
| Enniatin B | | 81% | 77 | 8 355 |
| Deoxynivalenol | | 81% | 621 | 43 891 |
| Enniatin B1 | | 81% | 30 | 3 262 |
| Beauvericin | | 76% | 60 | 2 056 |
| Zearalenone | | 68% | 82 | 4 412 |
| Fumonisin B1 | | 63% | 625 | 335 053 |
| Enniatin A1 | | 56% | 17 | 1307 |
| Fumonisin B2 | | 56% | 245 | 114 907 |
| Moniliformin | | 55% | 102 | 1 271 |
| Alternariol | | 50% | 23 | 3 672 |
| Fumonisin B3 | | 38% | 123 | 39 738 |
| Enniatin A | | 35% | 8 | 377 |
| Deoxynivalenol-3-Glucoside | | 32% | 134 | 2 379 |
| 15-Acetyl-Deoxynivalenol | | 18% | 239 | 3 813 |
| HT-2 Toxin | | 18% | 96 | 3 081 |
| Aflatoxin B1 | | 17% | 7 | 124 |
| T-2 Toxin | | 17% | 37 | 1255 |
| Ochratoxin A | | 12% | 6 | 331 |
| Sterigmatocystin | | 12% | 7 | 102 |
| Mycophenolic Acid | | 9% | 359 | 24 078 |
| Nivalenol | | 8% | 434 | 6 359 |
| 3-Acetyl-Deoxynivalenol | | 6% | 699 | 7 797 |
| Ergometrine | • | 5% | 19 | 93 |
| Aflatoxin B2 | • | 4% | 3 | 12 |
| Ergosine | | 3% | 13 | 141 |
| | 0% 50% Positive Sample | 100% es (%) | | |

Top25 metabolites are presented according to their prevalence (orange bars indicate regulated or guideline mycotoxins; red bar indicates a masked mycotoxin). Cut off for all metabolites 1 ppb (except for aflatoxins 0.5 ppb). Average of positive samples and maximum levels found are reported in ppb.

Ergot alkaloids

Regulated or guideline mycotoxins

Masked and modified myoctoxins

3-Acetyldeoxynivalenol and

15-Acetyldeoxynivalenol are metabolites of the mycotoxin Deoxynivalenol. They can be converted to Deoxynivalenol in the intestinal tract.

DON-3-glucoside: plant metabolite of DON (masked DON); less toxic than DON, but it converted back to DON in the gastrointestinal tract of mammals.

Aflatoxin B2 and G1: Aflatoxins, less toxic than Aflatoxin B1, not regulated

Nivalenol: Type B trichothecene, more cytotoxic than DON in intestinal cells of pigs and ruminants (in vitro)



Countries

FINISHED FEED (n=633)

| Metabolite | Prevalence | | Average | Maximum |
|----------------------------|------------|-----|---------|---------|
| Enniatin B1 | | 87% | 16 | 499 |
| Enniatin B | | 87% | 37 | 2654 |
| Deoxynivalenol | | 86% | 289 | 4 211 |
| Fumonisin B1 | | 77% | 179 | 6 305 |
| Beauvericin | | 76% | 24 | 224 |
| Zearalenone | | 74% | 24 | 324 |
| Moniliformin | | 69% | 64 | 673 |
| Fumonisin B2 | | 67% | 69 | 1106 |
| Enniatin A1 | | 64% | 8 | 123 |
| Alternariol | | 63% | 17 | 805 |
| Fumonisin B3 | | 51% | 37 | 432 |
| Enniatin A | | 43% | 4 | 69 |
| Aflatoxin B1 | | 27% | 4 | 98 |
| Deoxynivalenol-3-Glucoside | | 27% | 83 | 2 379 |
| Ochratoxin A | | 17% | 3 | 29 |
| Sterigmatocystin | | 14% | 5 | 36 |
| T-2 Toxin | - | 11% | 32 | 892 |
| 15-Acetyl-Deoxynivalenol | | 9% | 93 | 689 |
| HT-2 Toxin | - | 8% | 67 | 973 |
| Ergometrine | | 7% | 21 | 93 |
| Mycophenolic Acid | | 6% | 298 | 9 083 |
| 3-Acetyl-Deoxynivalenol | | 4% | 1159 | 7 752 |
| Ergosine | • | 4% | 18 | 141 |
| Ergotamine | • | 3% | 5 | 13 |
| Roquefortine C | • | 3% | 396 | 3 411 |

Top25 metabolites are presented according to their prevalence (orange bars indicate regulated or guideline mycotoxins; red bar indicates a masked mycotoxin). Cut off for all metabolites 1 ppb (except for aflatoxins 0.5 ppb). Average of positive samples and maximum levels found are reported in ppb.

| Emerging myotoxins | A |
|--|----|
| Emerging myotoxins: frequently found on | |
| agricultural commodities, not regulated; toxicity is | В |
| under investigation, but toxic effects suggested in | a |
| some scientific literature; EFSA started to publish | |
| reports to do a risk assessment for these toxins. | St |
| | ef |
| Moniliformin: broiler very susceptible, genotoxic, | ne |
| immunosuppressive; causes heart damage, | le |
| muscular weakness, respiratory distress | |
| | R |
| Mycophenolic acid: Mycophenolic Acid shows | ne |
| a low acute toxicity in animals but may cause | W |
| immunosuppression. | ly |

Positive Samples (%)

Alternariol: no acute toxicity, cytotoxic and mutagenic in *vitro*, effects on reproductive & immune system *in vitro*.

Beauvericin and Enniatins: effects on immune system: accumulation in fat-rich tissue.

Sterigmatocystin: precursor of aflatoxins; causes similar effects as aflatoxin B_1 in animals, but lower acute toxicity; negative effects incl. bloody diarrhea, less milk production, ess feed intake, hepatotoxicity, nephrotoxicity

Roquefortine C effects: low acute toxicity, associated neurotoxicity observed in chickens, cows and dogs when co-contaminated with penitrems. Reduced ymphocyte proliferation in vitro at high concentrations.

We bring progress to life



Scan to know more or visit dsm-firmenich.com/anh



dsm-firmenich 🚥